Jubilant Pharma Limited

Jubilant Pharma Limited is a Singapore-based company specializing in the development and supply of pharmaceutical products, particularly in the allergy and nuclear medicine sectors, catering to a diverse global clientele. Founded in 2003 and headquartered in Singapore, Jubilant Pharma Limited focuses on pharmaceutical manufacturing and services. The company operates with a dedicated team and has expanded its capabilities over the years to include a range of healthcare solutions. The CEO, Pramod Yadav, leads the company as it continues to innovate and serve its clients effectively.

Jubilant Pharma’s primary offerings encompass a diverse range of pharmaceutical products and services, focusing on the allergy and nuclear medicine sectors. The company’s HollisterStier Allergy division provides over 200 different allergenic extracts and standard allergy vaccine mixtures, catering to patients suffering from allergies across various demographics. This division has established itself as a leader in the immunotherapy industry in the United States over the past 90 years. In addition, Jubilant Radiopharma specializes in the production and supply of nuclear medicine products, leveraging its extensive manufacturing capabilities to support a global client base that includes innovator and generic pharmaceutical companies.

The geographical markets served include North America and select international regions, where their products are utilized in hospitals, specialty clinics, and pharmacies to enhance patient care and treatment outcomes. For the year 2023, Jubilant Pharma reported a revenue of USD 782. 69 mn and an EBITDA of USD 66. 28 mn.

The company derives its revenue from multiple streams, predominantly through B2B transactions with pharmaceutical companies and healthcare providers. It engages in direct sales of its allergy therapy products and nuclear medicine solutions, which are integral to patient treatment protocols. Transactions are structured as partnerships, with clients placing orders for both bulk supplies and specialized formulations tailored to their needs. Revenue may also be generated from collaborative agreements, such as their recent cooperative agreement with the U.

S. government aimed at expanding vaccine manufacturing capacity. The pricing structure for these products is influenced by the scale of purchase and specific client agreements, ensuring competitive positioning within the pharmaceutical market while maintaining a focus on quality and compliance with regulatory standards. Jubilant Pharma is committed to expanding its product offerings, including launching new allergy therapy solutions and enhancing its nuclear medicine portfolio.

The company seeks to enter new markets in Europe and Asia by 2025, aiming to establish a stronger regional presence. Recent funding will support these initiatives, facilitating the development of new products and the expansion of production capabilities.